Treating ovarian cancer: New pathways through genetics
A new discovery that sheds light on the genetic make up of ovarian cancer cells could explain why some women survive longer than others with this deadly disease.
A new discovery that sheds light on the genetic make up of ovarian cancer cells could explain why some women survive longer than others with this deadly disease.
Men with prostate cancer in Texas may be driving more than three times farther than needed to obtain radiation oncology treatments for their cancer when treated at a… read more.
Prostate cancer is one of the most common cancers in men and early treatment is usually very successful. However, like other cancers, obesity increases the risk of aggressive… read more.
Malignant cells that leave a primary tumor, travel the bloodstream and grow out of control in new locations cause the vast majority of cancer deaths.
Metformin, a drug widely used to treat Type II diabetes, may help to prevent primary liver cancer
Bladder cancer patients whose tumors express high levels of the protein CD24 have worse prognoses than patients with lower CD24.
The European Society for Medical Oncology (ESMO) announced today the names of two eminent cancer specialists and one European institution that will be recognized for their contribution to… read more.
Sleep apnoea severity has been associated with increased cancer mortality in a new study.
In a press release on August 8, 2012, Amgen announced that the company was halting a late-stage trial of its monoclonal antibody IGF-1 receptor antagonist ganitumab (AMG-479).
In news that is bound to excite breast cancer patients and investors, Genentech/Roche/Immunogen issued press releases on August 26, 2012, confirming that their drug-of-the-moment T-DM1 (trastuzumab emtansine) offers… read more.
by Zara Qadir reporting on the presentation by Yechiel Hekster (pictured), Professor of Clinical Pharmacy, and a member of The Netherlands Medicines Evaluation Board.
Zara Qadir interviews Dr Chantal Bélorgey (pictured), Head of Clinical Trial Development at the French national competent authority, Affsaps (Agence française de sécurité sanitaire des produits).
Advertisment
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.